News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NeoPharm (NEOL) Announces FDA Grant of Orphan Drug Designation for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis


5/17/2010 10:00:46 AM

LAKE BLUFF, Ill.--(BUSINESS WIRE)--NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan-drug designation for IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES